[ad_1]
China-Russia Approves Use of COVID-19 Vaccine Before Phase 3 Ends
It is also noted that the US ahead of the November presidential election will push for swift approval of the vaccine
The US Food and Drug Administration has suggested that the FDA may approve the COVID-19 vaccine prior to the phase 3 clinical trial.
If this happens, the credibility of the Corona 19 vaccine is expected to rise along with criticism that it is a conscious political decision of the presidential election.
Reporter Kim Hyung-geun about the report.
[기자]The director of the US Food and Drug Administration, Steve Han, said in an interview: “We are ready to approve the COVID-19 vaccine before the end of the phase 3 clinical trial.”
Is that you can quickly approve it quickly.
“But it will be enforced when the benefits of the vaccine outweigh the risks.”
In general, the vaccines are approved for use after passing rigorous phase 3 clinical trials to confirm safety and efficacy.
But earlier, China and Russia approved the use of the COVID-19 vaccine before the end of Phase III.
There are observations that the United States, ahead of the November presidential election, will also push for swift approval of the vaccine.
This is because President Trump has repeatedly emphasized vaccine development before the presidential election.
[도널드 트럼프 / 미국 대통령 : 백신에 관해서 그 날짜 무렵이 될 것이라고 낙관합니다. 올해 말 이전에 백신을 갖게 될 것으로 확실히 믿고 있습니다. 그 날짜(대선 일) 무렵이요? 네, 그렇다고 생각합니다.]Treasury Secretary Manusin and White House Secretary General Meadows also said they could approve the emergency use of the vaccine that has not recently completed Phase III.
Some believe that in this series of movements there is a calculation to change the electoral phase to an advantage by supplying vaccines before the presidential election.
However, if swift approval of the vaccine becomes a reality, criticism is unlikely.
This is because we will face criticism for neglecting the safety of the people to win the presidential election.
Furthermore, the reliability of vaccines, the safety of which is as important as their efficacy, can be compromised.
Because of this, the medical community and health scientists are very concerned about the rapid approval of the vaccine.
[아메시 아달자 / 존스홉킨스대 교수 : 백신이 얼마나 안전하고 효과적인지를 알기 전에 승인하는 것은 위험하다고 생각합니다. 안전하고 효과적인 백신을 만드는 것뿐만 아니라 대중들에게 자신감을 심어줘 백신을 맞기를 원하도록 유도해야 합니다.]Anthony Pouch, director of the National Institute of Allergy and Infectious Diseases, also voiced public opposition to the rapid development.
This is YTN Kim Hyung-geun.
